Peapod Lane Capital LLC lessened its holdings in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) by 57.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 71,418 shares of the company's stock after selling 95,425 shares during the quarter. Peapod Lane Capital LLC owned about 0.14% of Kodiak Sciences worth $200,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vontobel Holding Ltd. purchased a new position in shares of Kodiak Sciences during the 1st quarter worth $28,000. PNC Financial Services Group Inc. boosted its holdings in Kodiak Sciences by 1,501.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after purchasing an additional 2,988 shares in the last quarter. US Bancorp DE acquired a new position in Kodiak Sciences in the fourth quarter valued at approximately $40,000. Aries Wealth Management acquired a new stake in shares of Kodiak Sciences in the first quarter valued at approximately $70,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Kodiak Sciences in the fourth quarter valued at approximately $90,000. Institutional investors and hedge funds own 89.06% of the company's stock.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "neutral" rating and issued a $3.00 price objective on shares of Kodiak Sciences in a research report on Monday, March 31st.
Read Our Latest Analysis on KOD
Kodiak Sciences Stock Up 1.1%
Shares of KOD traded up $0.05 during trading hours on Thursday, reaching $4.49. 540,193 shares of the company traded hands, compared to its average volume of 347,167. The stock has a market capitalization of $236.91 million, a PE ratio of -1.24 and a beta of 2.28. Kodiak Sciences Inc. has a fifty-two week low of $1.92 and a fifty-two week high of $11.60. The stock has a fifty day simple moving average of $3.83 and a 200 day simple moving average of $4.75.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.20). Research analysts predict that Kodiak Sciences Inc. will post -3.45 EPS for the current fiscal year.
About Kodiak Sciences
(
Free Report)
Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Further Reading
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
